Role of Interleukin 1 in Antigen-Induced Exacerbations of Murine Arthritis


From the Department of Rheumatology, University Hospital St. Radboud, Nijmegen, The Netherlands

The mechanism underlying the chronic and intermittent course of rheumatoid arthritis is not elucidated. In the present study, the role of interleukin 1 (IL-1) was investigated in exacerbations of antigen-induced arthritis in mice. A flare-up of smoldering inflammation (weeks 3 to 4 of antigen-induced arthritis) was inducible by injection of a small amount of methylated bovine serum albumin into the hypersensitive knee joint. Immunohistochemistry showed IL-1 expression in the synovial lining layer and in focal areas of the inflamed synovium during the flare-up. IL-1 was also measured in 1-hour culture supernatant of synovial tissue taken during the flare-up by a bioassay. The expression of both immunoreactive and bioactive IL-1 in the hypersensitive joint peaked around 6 hours after antigen (2 μg of methylated bovine serum albumin) injection and declined thereafter. Antigen rechallenge induced an acute joint swelling of the arthritic joint but not in the naive joint of the sensitized mouse, yet synovia of both joints produced IL-1 after antigen injection. Remarkably, a single intravenous injection of rabbit anti-IL-1α and -β antibodies 1 hour before antigen rechallenge neutralized IL-1 in the joint. Anti-IL-1 treatment significantly reduced the antigen-induced joint swelling (30 to 40%) but did not affect the profound influx of polymorphonuclear cells in the onset of the exacerbation. However, a profound relief of the inflammation (synovitis) was obtained by IL-1 blockade on day 4 of the exacerbation. Chondrocyte proteoglycan synthesis was markedly suppressed in the antigen-challenged naive knee joints suggesting that this was a direct IL-1 effect as the inflammation was insignificant. Anti-IL-1 treatment was able to maintain chondrocyte proteoglycan synthesis in the antigen-rechallenged joint, which was highly suppressed in the control group. Furthermore, the enhanced proteoglycan breakdown in the antigen-rechallenged joints was significantly decreased in the anti-IL-1 group. We concluded that IL-1 is an important mediator in exacerbations of murine arthritis, and amelioration of cartilage pathology was obtained with anti-IL-1 antibody treatment. (Am J Pathol 1995, 146:239-249)

There is increasing evidence to suggest that the pluripotent cytokine interleukin-1 (IL-1) plays an important role in the pathogenesis of inflammatory joint diseases, including rheumatoid arthritis. IL-1 has been identified in the synovial membrane and cartilage-pannus junction of arthritic joints from patients with rheumatoid arthritis. Moreover, numerous studies reported a striking correlation between the IL-1 levels in rheumatoid synovial fluid or plasma and the disease activity in these patients. The two important features of arthritis, namely inflammation and cartilage destruction, can be attributed to local IL-1 activity. In several mammalian species it was demonstrated that IL-1 injected into the synovial joints causes an arthritic insult. In vitro studies showed that chondrocyte proteoglycan (PG) synthesis was more susceptible to IL-1 than chondrocyte-mediated PG degradation.

To prove the importance of IL-1, recent studies have addressed the effect of blocking IL-1 in experimental arthritis either by neutralizing IL-1 with antibodies or soluble IL-1 receptors or by antagonizing the IL-1 binding to its receptor with IL-1 receptor antagonist protein (IL-1ra) and related proteins (M20). These different therapeutic approaches were able to diminish joint inflammation and also to reduce cartilage destruction in collagen-induced arthritis (CIA), immune complex arthritis (ICA), and adjuvant arthritis.
and in the autoimmune prone MRL/lpr mice. In murine antigen-induced arthritis (AIA), anti-IL-1 treatment did not affect the acute joint inflammation (edema and influx of polymorphonuclear cells; PMNs) nor the accelerated PG breakdown, yet the marked chondrocyte PG synthesis inhibition was completely prevented. We were the first to demonstrate impressive reduction both in inflammation as well as in cartilage destruction in established CIA using rabbit anti-IL-1 polyclonal antibody treatment. These studies at least suggest that IL-1 blockade is worth pursuing as a therapeutic strategy for human arthritis.

In 70% of patients with rheumatoid arthritis, the disease is characterized by an intermittent course of inflammation. In humans, a rise in plasma IL-1 levels followed the secondary flare-ups in RA, and isolated peripheral monocytes spontaneously produced IL-1 during the flare-up. In the present study, experiments were carried out to examine the role of IL-1 in the flare-up with an animal model. A flare-up of smoldering inflammation in the chronic phase of AIA was inducible in a predictable and synchronized manner by injection of a small amount of methylated bovine serum albumin (mBSA) into the hypersensitive knee joint.

Recently, Schwab et al demonstrated that IL-1 played a key role in the peptidoglycan-poly saccharide polymer reactivation of streptococcal cell wall-induced arthritis. It cannot be excluded that at least part of the flare-up reaction in this model was nonimmunologically mediated. Apart from peptidoglycan-poly saccharide, flares-ups can also be induced with cell wall-derived lipopolysaccharide and these fragments can directly activate macrophages. In AIA, T lymphocytes, as part of the residual inflammation in the arthritic joints, mediated the antigen-induced flare-up. Antigen-stimulated T cells could either produce IL-1 themselves or stimulate IL-1 production in other cells. In rheumatoid arthritis, it is still a matter of debate whether the arthritic process was driven by T cells, immune complexes (IC), or both or by nonimmunological pathways. Our study clearly demonstrates that IL-1 plays a key role in the antigen-induced exacerbation of murine arthritis.

Cytokines

Mature recombinant IL-1α and IL-1β were a generous gift from I. G. Otterness (Pfizer Central Research, Groton CT).

Generation of Rabbit Anti-Mouse IL-1 Antiserum

Rabbits were immunized with murine recombinant IL-1α or IL-1β, according to the method described by Hogquist et al with some modifications. In short, 250 μg of IL-1 in 2.25 ml of phosphate-buffered saline (PBS) was emulsified with 500 μl of Immune Alum (alum inum hydroxide; Pierce Chemical Co., Rockford, IL). Each rabbit received four subcutaneous injections (500 μl each) of the IL-1/Alum suspension at the back of the animal and adjacent to each of these sites, four 500-μl injections of complete Freund's adjuvant (C.F.A)/PBS subcutaneously. Each rabbit received three booster injection of 50 μg of IL-1/Alum, adjacent injections with incomplete Freund's adjuvant emulsified in PBS, and additionally 5 μg of IL-1 intravenously every 4 to 6 weeks. Ten days after every booster, 50 ml of blood were aspirated, coagulated, decomplemented at 56 C, and stored at −70 C. The neutralizing capacity was 300 μg of IL-1 per ml of the pooled antiserum.

Purification and Characterization of Rabbit Anti-IL-1 Antibodies

Immunoglobulins were purified by affinity chromatographic separation on a protein G sepharose 4B (albu min binding region genetically deleted; Sigma Chemical Co., St Louis, MO) column. Immunoglobulins were eluted with 0.1 mol/L glycine-hydrochloride, pH 3.0, and immediately neutralized with 50 mmol/L Tris-HCl, pH 8.0. Fractions were pooled, concentrated, and dialyzed against PBS at room temperature (RT). The anti-IL-1 antibodies showed no neutralizing reactivity against the other IL-1 subtype, IL-2, IL-4, IL-6, or tumor necrosis factor.

Generation of Rat Anti-Mouse IL-1 Antiserum

Wistar rats were injected subcutaneously with 50 μg of murine recombinant IL-1β emulsified in 0.5 ml of CFA. After 2 weeks, a booster injection was given of 25 μg of IL-1 in 0.5 ml of CFA. Rats were bled by orbital puncture at a regular basis 2 weeks after the booster injection.

Materials and Methods

Animals

Female New Zealand White rabbits, male Wistar rats, and male C57Bl/6 mice (Jackson Laboratories, West Grove, PA) were fed a standard diet and tapwater ad libitum.
Flare-Up of Arthritis

Mice of 8 to 12 weeks of age received subcutaneously 100 μg of mBSA (Sigma), emulsified in 100 μl of CFA, per animal. Injections were divided over both flanks and footpads of the forelegs. Heat-killed (2 × 10^9) *Bordetella pertussis* organisms (National Institute of Public Health, Bilthoven, The Netherlands) was administered intraperitoneally as an additional adjuvant. Mice received two booster injections of 50 μg of mBSA/CFA in the neck region on day 7. Three weeks later, arthritis was induced by injection of 6 μl containing 60 μg of mBSA in saline into the right knee joint cavity. At week 3 or 4 of arthritis, 0.2 to 2 μg of mBSA were injected intra-articularly into the arthritic joints to induce a flare-up of smoldering inflammation.

Joint Swelling

Mice were sedated by intraperitoneal injection of 0.25 ml of a 4.5% chloral hydrate solution per mouse. Approximately 10 μCi 99mTcTechnetium pertechnetate (99mTc) in 0.2 ml of saline were injected subcutaneously in the neck region. After 15 minutes the accumulation of the isotope in the knee was determined by external gamma counting and expressed as the ratio of 99mTc uptake in the inflamed to 99mTc uptake in the contralateral knee joint. A ratio higher than 1.1 indicates joint swelling.

IL-1 Production by Synovial Tissue

Patellae were dissected with surrounding soft tissue consisting of the tendon and synovium in a standardized manner. Each patella was incubated in 200 μl of serum-free RPMI 1640 (Dutch modification) medium with Glutamax-1 (GIBCO BRL, Life Technologies, UK) for 1 hour at RT. Dilutions of these washouts were tested for IL-1 and IL-2 bioactivity.

Bioassay for IL-1

IL-1 activity was measured in the one-stage bioassay for IL-1 as described by Gearing et al. The murine thymoma cell line EL-4 NOB-1 (ECACC, Porton Down, Salisbury, UK) was used as an IL-1-specific cell producing IL-2 in response, in combination with the IL-2-sensitive CTLL-2 cells (ECACC). The cells were plated out in concentrations of 1 × 10^6 NOB1 cells per well and 4 × 10^3 CTLL cells per well in RPMI supplemented with 5% fetal calf serum. After 18 to 20 hour, 0.5 μCi of [3H]thymidine (specific activity, 20 Ci/mmol; Dupont NEN Products, Boston, MA) were added per well. After 3 hours, cells were harvested and thymidine incorporation (NOB1 cells are thymidine kinase deficient) was determined. Detection limit of the assay was 0.1 pg/ml murine recombinant IL-1.

Assessment of Proteoglycan Synthesis

Patellae (n = 6), in a minimal amount of adjoining soft tissue (parts of synovium, tendon, and muscle), were placed in 2 ml of RPMI 1640 medium with gentamicin (50 μg/ml) and 40 μCi [35S]sulfate. At the end of the 3-hour incubation period, patellae were fixed in 10% formalin and subsequently decalcified in formic acid (4%), dissected, and dissolved in 0.5 ml of Lumasolve (Hicoul, Oud-Beijerland, The Netherlands). The [35S] content of each patella was measured by liquid scintillation counting and expressed as counts per minute (cpm) or as a percentage of normal cartilage.

Histology

Standard frontal sections (7 μ) of the whole knee joint, including both menisci, cruciate ligaments, and the patella, were prepared and mounted on 2% gelatin-coated slides as previously described. Slides were stained with safranin-O and counterstained with fast green. Cartilage depletion (diminished red staining) and inflammation were scored by a blinded observer.

Autoradiography

[35S]sulfate (100 μCi) (specific activity, 1200 to 1400 Ci/mmol; Dupont NEN) was injected intraperitoneally 6 hours before dissection of the knee joints. After histological processing, 7-μ sections mounted on 2% gelatin-coated slides as previously described. Slides were stained with safranin-O and counterstained with fast green. Cartilage depletion (diminished red staining) and inflammation were scored by a blinded observer.

IL-1 Immunostaining

Paraffin-embedded sections were mounted on 2% gelatin-coated slides, deparaffinized in xylene for 5 minutes twice, and rehydrated to deionized water. Endogenous peroxidase activity was blocked with 1% H2O2, in PBS for 20 minutes at RT. Slides were then rinsed in water and incubated overnight with the primary antibody, rat anti-IL-1β antiserum, or irrelevant rat antibody, diluted 1/150 in PBS plus 5% nonfat dry milk.
milk at 4°C in a humidified box. Were washed in excess PBS plus 0.1% Tween 20, three times for 10 minutes each time and incubated with biotinylated secondary antibody, rabbit anti-rat antibody diluted 1/200 in PBS plus 5% nonfat dry milk and 2% normal mouse serum for 1 hour at RT. They were then washed again in PBS/Tween 20 three times for 10 minutes each time. Avidin-biotin-peroxidase conjugated complex was prepared according to the directions for preparation (Vectastain ABC kit; Vector Laboratories, Burlingame, CA). Slides were incubated with the ABC reagent diluted in PBS plus 5% nonfat dry milk for 30 minutes at RT and washed again in PBS/Tween 20. Slides were then developed with 0.5 mg/ml diaminobenzidine in Tris-HCl, pH 7.6, and 0.02% H2O2 for 10 minutes and counterstained with hematoxylin for 15 seconds. Anti-IL-1 antibody was preincubated on IL-1α-coated plates, eight times for 20 minutes each at RT, or normal rat serum was used as a negative control. For control of IL-1α specificity, antiserum was preincubated on IL-1α- or BSA-coated plates.

**Treatment of Mice with Anti-IL-1 Antibodies**

Mice received 200 μl of a standard dose of 1 mg of purified rabbit anti-IL-1α antibody and 1 mg of anti-IL-1β antibody intravenously into the orbita plexus 1 hour before induction of the flare-up. These antibodies had an excellent half-life of more than 3 days in the blood circulation as was assessed by enzyme-linked immunoabsorbent assay. Total neutralizing capacity of the received dose was approximately 32 ng of both subtypes of IL-1 as was tested in the IL-1 bioassay (NOB-1) and blocked the effect of 1 ng of IL-1α or -β on PG synthesis completely and that of 10 ng of IL-1 partially in vivo (not shown). Normal rabbit IgGs or polyclonal anti-ovalbumin antibodies served as controls for nonspecific effects of the treatment.

**Results**

**IL-1 Expression in Antigen-Rechallenged Knee Joints of Chronic Arthritis**

At the time of antigen rechallenge, week 3 of AIA, a single intra-articular injection of a small amount of antigen (2 μg of mBSA) caused a transient expression of cell-associated IL-1β. The number of IL-1β-positive cells was small in the joint sections taken at 1 hour, high at 3 hours, low but still evident at 6 and 12 hours, and absent at 24 hours after the antigen rechallenge (not shown). The IL-1β signal was predominantly localized in the synovial lining layer and frequently in focal areas in the inflamed synovium (Figure 1). No immunostaining was evident with normal rat serum or with anti-IL-1α antiserum preincubated on microtiter plates coated with murine recombinant IL-1β (Figure 1). In some sections, chondrocytes and the exudate PMNs were nonspecifically stained.

A single intra-articular injection of mBSA into hypersensitive joints (week 3 of AIA) caused a dose-related joint swelling at 6 hours (Figure 2). Synovial tissue culture supernatants demonstrated increased levels of IL-1 bioactivity 6 hours after antigen rechallenge in the tested dose range of 0.06 to 2 μg of mBSA (Figure 2). Time course experiments demonstrated a rapid onset of joint swelling increasing at least up to 24 hours after antigen (2 μg mBSA) rechallenge of AIA (Figure 3). The level of bioactive IL-1 in synovial tissue culture supernatants of arthritic joints was high 3 and 6 hours after antigen rechallenge (Figure 3). The expression of IL-1 was more transient compared with joint swelling. At 24 hours after antigen injection, IL-1 released by the synovial tissue was low yet joints were profoundly swollen. Joint swelling was not inducible with 2 μg of mBSA injected into naive joints of sensitized animals (Figure 3). Interestingly, the antigen-challenged naive joints released IL-1 in levels and time course comparable with the rechallenged arthritic joints (Figure 3).

**Role of IL-1 in the Antigen-Induced Exacerbation of Chronic Joint Inflammation**

At the time of antigen rechallenge, week 3 of AIA, swelling of the arthritic joints subsided and the inflammatory exudate cells disappeared, but joints had a mild ongoing synovitis (Table 1). Intra-articular injection of 2 μg of mBSA into the arthritic joints caused an acute transient joint swelling (Table 1). On day 2 of the flare-up a Tc ratio of 1.22 ± 0.14 was measured (not shown). The same antigen dose injected into the naive contralateral joints of these arthritic animals did not cause joint swelling (Table 1). To investigate the role of de novo synthesized IL-1, neutralizing polyclonal anti-IL-1α and -β antibodies were injected intravenously 1 hour before antigen rechallenge. Blocking IL-1 decreased joint swelling by 29% at 6 hours and significantly reduced joint swelling by 41% at 24 hours after antigen rechallenge as compared with untreated mice (Table 1). This was a
consistent finding in all experiments: mean joint swelling of 1.60 ± 0.21 in the untreated mice (n = 47), 1.52 ± 0.24 in the normal rabbit IgG-treated mice (n = 68), and 1.37 ± 0.29 in the anti-IL-1-treated mice (n = 75) on day 1 after antigen rechallenge.

Antigen injection also caused a marked influx of polymorphonuclear neutrophils (PMN) into the cavity and exacerbated the ongoing synovitis in the hypersensitive joint (Table 1). A moderate inflammation was inducible in the naive contralateral joints of these sensitized animals with the same antigen dose (2 μg of mBSA) used (Table 1).

Anti-IL-1α and -β antibody pretreatment had no effect on the number of inflammatory cells (PMN) in the 6- and 24-hour exudate and on the extent of the synovitis at these time points (Table 1). A marked amelioration of the synovitis was observed on day 4 after antigen rechallenge in the anti-IL-1-treated group (Table 1 and Figure 4). This was a consistent finding in three out of a total of four experiments. Synovitis in the normal rabbit IgG-treated mice (1.55 ± 0.69, n = 21) was significantly higher than in the anti-IL-1-treated mice (0.63 ± 0.23, a reduction of 59%).

**Role of IL-1 in the Flare-Up Related Cartilage Pathology**

Chondrocyte PG synthesis, markedly suppressed for the first weeks of AIA, returned to a normal rate at week 3 of AIA. A marked suppression of PG synthesis was evident on day 1 (~28%) and day 2 (~23%) after antigen rechallenge in patellar cartilage as was measured by [35S]sulfate incorporation ex vivo (Table 2). Pretreatment of mice with anti-IL-1 antibodies completely prevented the PG synthesis suppression to occur (Table 2). Autoradiography of whole knee joint sections also demonstrated reduced [35S]sulfate incorporation by chondrocytes in the cartilage of arthritic joints from day 1 up to day 4 after antigen rechallenge (Table 3 and Figure 5). Blocking IL-1 activity with antibodies significantly enhanced PG synthesis in antigen-rechallenged mice (Table 3 and Figure 5). Interestingly, injection of 2 μg of mBSA into the naive contralateral joints of these mice also resulted in a significant suppression of PG synthesis on day 1 (Tables 2 and 3).
Enhanced PG degradation (-59%) was found in the hypersensitive joints 1 day after antigen rechallenge as was measured on [35S]sulfate prelabeled patellar cartilage in vivo (Table 2). The accelerated degradation could be significantly reduced by anti-IL-1 treatment but was still remarkable (-37% Table 2).

Histology taken at week 4, but not at week 3, of AIA showed full recovery of the cartilage matrices (Figure 3). Antigen (2 µg of mBSA) rechallenge caused severe PG depletion of the cartilage matrices as was shown on safranin-O-stained whole knee joint sections (Table 3 and Figure 4). Pretreatment with anti-IL-1 antibodies, but not with control IgG, significantly ameliorated the cartilage pathology on day 4 of the antigen-induced exacerbation (Table 3 and Figure 4). Anti-IL-1α and -β pretreatment completely prevented the antigen-induced cartilage depletion in the hypersensitive joints in four of five experiments. Antigen injection into the naive contralateral joints of the arthritic mice caused only minor cartilage depletion (Table 3).

Discussion

This study clearly demonstrates that IL-1 is an important determinant in antigen-induced exacerbations of murine arthritis. In the conducted experiments, pretreatment of mice with rabbit polyclonal antibodies directed against murine recombinant IL-1α and IL-1β markedly alleviated joint swelling and ameliorated cartilage pathology of the antigen-rechallenged joints.

Using avidin-biotin immunohistochemistry, we showed IL-1β expression in the synovium of antigen-rechallenged joints, predominantly located in the lining layer and in distinct cell clusters in the sublining layer and in single cells sparsely distributed in the deeper area. An identical localization was also found in synovial membranes of rheumatoid arthritis for IL-1α and IL-1β. The expression of IL-1α was identical to IL-1 in the rheumatoid synovium although the number of positive cells was considerably smaller. We found identical kinetics for the expression of both bioactive and immunoreactive IL-1 in hypersensitive joints after antigen rechallenge. This indicates that IL-1 inhibitors (eg, IL-1ra), although they may be produced, were not responsible for the transient expression of bioactive IL-1 in the flare-up.

IL-1 was inducible in both virgin and hypersensitive joints of sensitized mice but not in joints of normal mice. This shows that the stimulation of IL-1 was not a property of the antigen but that either antigen-specific T lymphocytes or immunoglobulins were involved. IL-1 production in rheumatoid synovial membranes was considerably higher in membranes possessing lymphocyte aggregates compared with membranes with a disperse infiltrate. These focal areas are composed of B cells, plasma cells, and CD4+ T cells in the center and macrophages in the periphery. Not only T helper type 2 cells but also B cells, as almost all accessory cells (eg, macrophages), can produce IL-1. We did not quantitatively...
Role of IL-1 in the Flare-Up of Arthritis

Table 1. Role of IL-1 in the Antigen-Induced Exacerbation of Smoldering Joint Inflammation

<table>
<thead>
<tr>
<th>Antigen*</th>
<th>Pretreatment</th>
<th>Joint swelling Tc ratio†</th>
<th>Histological analysis</th>
<th>Joint swelling Tc ratio†</th>
<th>Histological analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>6 hours (n = 8)</td>
<td>24 hours (n = 12)</td>
<td>6 hours (n = 7)</td>
<td>24 hours (n = 8)</td>
</tr>
<tr>
<td>None</td>
<td>None</td>
<td>1.07 ± 0.07</td>
<td>1.05 ± 0.08</td>
<td>0.0 ± 0.0</td>
<td>0.0 ± 0.0</td>
</tr>
<tr>
<td>+</td>
<td>Normal rabbit serum</td>
<td>1.49 ± 0.26</td>
<td>1.70 ± 0.10</td>
<td>1.4 ± 0.5</td>
<td>1.7 ± 0.9</td>
</tr>
<tr>
<td>+</td>
<td>Anti-IL-1α and -β</td>
<td>1.46 ± 0.15</td>
<td>1.66 ± 0.20</td>
<td>1.8 ± 0.9</td>
<td>1.8 ± 0.6</td>
</tr>
<tr>
<td>+</td>
<td>None</td>
<td>1.35 ± 0.23</td>
<td>1.41 ± 0.17</td>
<td>1.6 ± 1.0</td>
<td>1.8 ± 0.8</td>
</tr>
</tbody>
</table>

* Arthritic knee joints rechallenged with 2 μg of mBSA at week 3 of AIA (+). For the last row, antigen was injected into the naive contralateral knee joints.† Joint swelling was measured at 6 and 24 hours after antigen injection by Tc uptake. Results are expressed as ratio of uptake in inflamed to uptake in contralateral knee joint + SD.‡ Histological analysis of cell exudate (PMNs) in the joint cavity at 6 and 24 hours after antigen injection. Arbitrary scoring from 0 (no cells) to 3 (large number of inflammatory cells) by a blinded observer.§ P < 0.05 was considered significant, as tested by using the Wilcoxon's rank sum tests.

Figure 4. Histology of whole knee joint sections stained with safranin O. A. Arthritic knee joint at week 4 of AIA. B. Arthritic joint in a normal rabbit IgG-treated mouse 4 days after antigen rechallenge (2 μg of mBSA). Note the thickening of the synovial lining arrows and PG loss in the cartilage matrix (compact arrow). C. Antigen-rechallenged joint in an anti-IL-1 antibody-treated mouse. Original magnification, × 100. P, patella; F, femur; JS, joint space; S, synovium; C, cartilage.

compare the IL-1 production in antigen challenged naive and hypersensitive joints, but only in the latter did we find distinct staining of cell clusters.

The antigen dose used for the flare-up of AIA did not induce inflammation when injected in normal knee joints of sensitized mice. This suggests that the antigen-induced IL-1 production was too low to induce joint inflammation in normal joints. This is in agreement with a previous study of ours in which we showed that a single injection of 10 ng of IL-1 did not induce joint swelling or cell exudate in naive joints but induced a brief flare-up of the inflammation in arthritic joints of AIA. H. A highly likely explanation for this hypersensitive state could be the increased expression of adhesion molecules (VCAM-1 and intercellular adhesion molecules) in the inflamed synovium. 31

In the present study we found, using anti-IL-1α and -β antibodies, that the cell exudate and the joint swelling for the greater part (60 to 70%) were not IL-1 mediated in the antigen-induced exacerbation of AIA, and this suggests that other mediators are involved in this process. Possible candidates are T cell-derived mediators. Evidence was presented that CD4 T cells are mediating the antigen-induced exacerbation of murine arthritis. 32 It was concluded that the blockade of the flare-up by anti-la (histocompatibility type II antigens) antibodies that antigen presentation was of importance. 26 Although IL-1 is capable of ac-
activation, suggesting that the latter was not solely T
ther IL-1 nor tumor necrosis factor-α dependent, in
superantigen, toxic shock syndrome toxin 1, was nei­
inflammatory cytokines during antigen-induced exac­
titation of AIA.

amounts of IL-2 or IL-4 with the antigen significantly
flare-up are different from each other. Evidence is
and this implies that the antigen- and IL-1-induced
reactivation of lymphocytes, we found that the IL-1-induced
exacerbation of AIA was not lymphocyte mediated,
and this implies that the antigen- and IL-1-induced flare-up are different from each other. Evidence is emerging that IL-1 does not play a prominent role in antigen-induced T cell activation. We selectively blocked the Th1-derived IL-2 and the Th2-derived IL-4 with antibodies and this markedly reduced joint swelling, cell exudate, and infiltrate during the antigen-induced flare-up. Co-injection of large amounts of IL-2 or IL-4 with the antigen significantly enhanced cell exudate. We concluded that the T cell-derived cytokines IL-2 and IL-4 are acting as proinflammatory cytokines during antigen-induced exacerbation of AIA.

Schwab et al demonstrated that reactivation of streptococcal cell wall-induced arthritis by the T cell superantigen, toxic shock syndrome toxin 1, was neither IL-1 nor tumor necrosis factor-α dependent, in contrast with the peptidoglycan polysaccharide reactivation, suggesting that the latter was not solely T cell mediated. A more important role of IL-1 was found in IC-mediated inflammations. Recently we developed an IC-mediated arthritis model (ICA) by passive immunization in the mouse. In this model, IL-1 and complement activation acted synergistically in the onset of inflammation. Striking anti-inflammatory effects with anti-IL-1 antibodies or IL-1 receptor antagonist protein (IL-1ra) were also found in CIA, even when treatment was started in already established disease. In contrast, anti-IL-1 treatment had no effect on the onset of AIA. CIA is probably more IC than T cell mediated. For instance, although CIA could be transferred by T cells or IC, a combination resulted in a more pronounced inflammation. However, AIA and the subsequent hypersensitive state of the joints could be transferred with antigen (mBSA)-specific T cells to naive recipients. Up until now, we were unable to transfer the disease (AIA) by B cells or immunoglobulins (unpublished data). The importance of IL-1 could be related to the type or the site of the inflammation.

<table>
<thead>
<tr>
<th>Antigen*</th>
<th>Treatment†</th>
<th>Synthesis day 1 (n = 7)</th>
<th>Synthesis day 2 (n = 7)</th>
<th>Degradation day 1 (n = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>None</td>
<td>1118 ± 104</td>
<td>1238 ± 259</td>
<td>360 ± 99</td>
</tr>
<tr>
<td>+</td>
<td>None</td>
<td>739 ± 54 (−26%)</td>
<td>958 ± 251 (−23%)</td>
<td>ND</td>
</tr>
<tr>
<td>+</td>
<td>Anti-IL-1</td>
<td>732 ± 103 (−36%)</td>
<td>913 ± 343 (−26%)</td>
<td>148 ± 39 (−59%)</td>
</tr>
<tr>
<td>None</td>
<td>NRS</td>
<td>1059 ± 143 (−4%)</td>
<td>1519 ± 778 (−23%)</td>
<td>226 ± 40 (−37%)</td>
</tr>
<tr>
<td>+</td>
<td>None</td>
<td>1153 ± 256</td>
<td>ND</td>
<td>ND</td>
</tr>
<tr>
<td>+</td>
<td>NRS</td>
<td>860 ± 170 (−25%)</td>
<td>ND</td>
<td>ND</td>
</tr>
</tbody>
</table>

* Arthritic knee joints rechallenged with 2 μg of mBSA at week 3 of AIA (+). For the last two rows, antigen was injected into naive contralateral knee joints.
† Normal rabbit antibodies (NRS) or anti-IL-1α and -β antibodies injected 1 hour before antigen rechallenge.
‡ Autoradiography of whole knee joint sections. §Sulfate incorporation into patellar cartilage ex vivo. Values in parentheses indicate the inhibition of PG synthesis as a percentage of the unchallenged joint. Representative of two experiments.
¶ Sulfate content in patellar cartilage. [35S]Sulfate was injected subcutaneously 24 hours before antigen injection.
§ P < 0.05 was considered significant, as tested by using the Student's t-test.

| Antigen* | Treatment | Degradation Degradation Degradation Degradation |
|----------|-----------|------------------------|------------------------|-------------------------|
| None     | None      | 2.0 ± 0.9              | 2.2 ± 0.3              | 2.1 ± 0.9               | 0.4 ± 0.8               |
| +        | None      | 0.5 ± 0.3 (−77%)       | ND                     | ND                      | 2.1 ± 0.8               |
| +        | NRS       | 0.7 ± 0.4 (−70%)       | 0.9 ± 0.6 (−60%)       | 0.9 ± 0.7 (−60%)        | 1.9 ± 0.9               |
| +        | Anti-IL-1  | 1.4 ± 0.7 (−30%)       | 1.9 ± 0.7 (−14%)       | 2.5 ± 0.5 (−17%)        | 0.3 ± 0.5               |
| None     | None      | 1.3 ± 0.6              | ND                     | ND                      | 0.0 ± 0.0               |
| +        | None      | 0.5 ± 0.3 (−63%)       | ND                     | ND                      | 0.4 ± 0.2               |

* Arthritic knee joints rechallenged with 2 μg of mBSA at week 4 of AIA (+). For the last two rows antigen was injected into naive contralateral knee joints.
† Normal rabbit antibodies (NRS) or anti-IL-1α and -β antibodies injected 1 hour before antigen rechallenge.
‡ Autoradiography of whole knee joint sections. §Sulfate incorporation into patellar cartilage ex vivo. Values in parentheses indicate the inhibition of PG synthesis as a percentage of the unchallenged joint.
¶ Histological analysis of patellar cartilage PG depletion as scored arbitrarily from 0 (strong safranin-O staining, no depletion) to 3 (strong blackening as seen in the growth plates). Values in parentheses indicate PG synthesis inhibition as a percentage of the unchallenged joint.
§ P < 0.05 was considered significant, as tested by using the Wilcoxon's rank sum tests.
Antigen rechallenge of the hypersensitive joints induced a marked inhibition of chondrocyte PG synthesis for at least 4 days. This was not a property of the antigen as PG synthesis suppression was not inducible in joints of nonimmune mice. The flare-up of the inflammation was also not responsible for the suppression of the chondrocyte synthetic function for two reasons. First, antigen injection into naive joints of sensitized mice induced both IL-1 production and inhibition of PG synthesis without a significant joint inflammation. Second, blocking IL-1 with neutralizing anti-IL-1α and -β antibodies protected the chondrocyte synthetic function without affecting the onset of the flare-up. We previously demonstrated a key role of IL-1 in the inhibition of PG synthesis in several murine arthritis models, i.e., CIA, AIA, and ICA.

The enhanced cartilage degradation in the antigen-challenged arthritic joints was, for approximately 50%, IL-1 mediated. In ICA and CIA, the anti-IL-1 also significantly reduced PG degradation, but this was probably related to the alleviation of joint inflammation. A more likely explanation for the protective effect of anti-IL-1 treatment on the flare-up is a higher vulnerability for IL-1-induced degradation of cartilage in the recovery phase of arthritis (manuscript in preparation). Pelletier et al presented evidence for an enhanced number of IL-1 receptors on chondrocytes in human osteoarthritic cartilage and showed that the IL-1 required for half-maximal metalloproteinase stimulation was three to four times lower compared with normal cartilage.

Protection of the chondrocyte synthetic function and reduction of the enhanced PG degradation probably resulted in the observed amelioration of the cartilage pathology on day 4 after antigen rechallenge. Mini-osmotic pumps releasing 30 µg of IL-1ra per hour into the peritoneal cavity from day 2 before antigen rechallenge up to 7 days thereafter verified the anti-IL-1 antibody effects (not shown).

Another impressive effect of the anti-IL-1 treatment was the reduction in the synovial thickness (hyperplasia) on day 4 of the exacerbation. IL-1 is a potent growth factor for synovial fibroblasts, which can explain this anti-IL-1 effect. Synoviocytes can actively participate in the local hypersensitivity for a number of reasons. First, synovial fibroblasts (synoviocytes) are accessory cells by their capacity of antigen presentation and IL-1 expression. Second, adhesion molecules can be induced by cytokines on type B synoviocytes, which may facilitate leukocyte recruitment. Moreover, unrestricted synoviocyte proliferation caused arthritis in animals and synovial tissue implants caused cartilage destruction. Therefore, the reduction of the synovial hyperplasia in the antigen-rechallenged joints could be responsible for the amelioration of arthritis.

This study indicates that IL-1 is involved as key mediator in the pathological changes of cartilage, not only in IC-mediated inflammation but also in T cell-mediated inflammation. Our study strengthens the need for additional research of the role of IL-1 even when IL-1 is not involved in the onset of inflammation.
References


27. Hogquist KA, Nett MA, Sheehan KCF, Pendleton KD, Schreiber RD, Chaplin DD: Generation of monoclonal...
antibodies to murine IL-1β and demonstration of IL-1 in vivo. J Immunol 1991, 146:1534–1540


32. Jacobs MJM, van den Hoek AEM, van Lent PLEM, van de Loo FAJ, van de Putte LBA, van den Berg WB: Role of IL-2 and IL-4 in exacerbations of murine arthritis. Immunology 1994, 83:390–396

33. Nicod LP, el-Habre F, Dayer JM: Natural and recombinant interleukin 1 receptor antagonist does not inhibit human T-cell proliferation induced by mitogens, soluble antigens or allogeneic determinants. Cytokine 1992, 4:29–35


42. Van Lent PLEM, van de Loo FAJ, Holthuysen AEM, van den Bersselaar LAM, Vermeer H, van den Berg WB: Major role for IL-1 but not for TNF in early cartilage damage in immune complex arthritis in mice. J Rheumatol, in press


